Dx Deals: Quest Closes PathAI Partial Acquisition and Strategic Alliance
Deal is expected to give the lab giant a big boost in deploying artificial intelligence in the pathology space.
Keeps You Up-to-Date on Lab Business and Competitive Strategy, Market Trends and Opportunities, and M&A and Investment Activity in Today’s Diagnostic Lab Industry
Deal is expected to give the lab giant a big boost in deploying artificial intelligence in the pathology space.
From - Laboratory Industry Report
The pace of diagnostic deal making picked up from the end of March through mid-April. Here's a quick overview of the activity and…
From - Laboratory Industry Report
Qiagen was the most active firm of the period with a trio of new product launches, including the US launch of…
From - Laboratory Industry Report
After a couple of years of dormancy, the FDA laboratory developed test (LDT) enforcement volcano stirred on…
From - Laboratory Industry Report
Greek philosopher Heraclitus said the only thing constant is change. Although he never managed a diagnostic lab…
By Steve Selbst bio
The purpose of this article is to help you, as a provider, to focus on three key items to look for in payer contracts that will help you to get profitable contracts in place…
From - Laboratory Industry Report
March was the most intense month of the year so far for new diagnostic products highlighted by 23andMe's launch of a new…